[A case of hypercalcemia with ovarian carcinoma]. 1988

M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
Dept. of Intern. Med., Kakogawa Municipal Hospital.

A 45-year-old female manifested lower abdominal fullness and symptoms of hypercalcemia with nausea, vomiting, and thirst. Physical examination showed a right ovarian mass and laboratory data demonstrated hypercalcemia (14.6 mg/dl). The radiographic findings confirmed a right ovarian tumor without any evidence of bone metastasis. Tests revealed that her PTH, nephrogenic urinary cyclic AMP, and 1-25 (OH)2 Vitamin D were not high but that her prostaglandin E2 (PGE2) was elevated. After correction of her calcium elevation with infusion and prednisolone, right oophorectomy with tumor excision was performed. A histological examination of the tumor revealed a mucinous cysto-adenocarcinoma. The postoperative course has been uneventful, with normal calcium and PGE2 values. This case illustrates that hypercalcemia associated with an ovarian carcinoma (Malignancy-associated hypercalcemia) can be mediated by the patient's PGE2 in part.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003536 Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed) Cystadenocarcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006934 Hypercalcemia Abnormally high level of calcium in the blood. Milk-Alkali Syndrome,Hypercalcemias,Milk Alkali Syndrome,Syndrome, Milk-Alkali
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2

Related Publications

M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
January 1995, Annales de pathologie,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
February 1975, Rocky Mountain medical journal,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
October 2008, Japanese journal of clinical oncology,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
January 2021, The American journal of case reports,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
September 1981, Cancer,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
January 1983, Zentralblatt fur Gynakologie,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
January 2002, Archives of pediatrics & adolescent medicine,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
February 1997, Hinyokika kiyo. Acta urologica Japonica,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
January 1992, The Kurume medical journal,
M Miura, and M Hashiramoto, and K Matsuda, and O Nakano, and K Suzuki, and M Maeda, and K Okada, and T Chinzei, and K Yamashiro, and M Harui
June 1981, Obstetrics and gynecology,
Copied contents to your clipboard!